17 Avr Genetic Engineering & Biotechnology News : Tech advances will help cell therapy makers cope with variable starting materials
« Autologous cell therapies are made from living cells, harvested from specific people. Every batch of inputs is different which makes predicting how each will perform in manufacturing a major challenge.Indeed, for Matthieu de Kalbermatten, CEO of France-based cell therapy developer CellProthera, starting material variability is the major issue facing the industry. »
Genetic Engineering & Biotechnology News | Gareth John Macdonald | April 5, 2023